CS
PCVX icon

Candriam SCA’s Vaxcyte PCVX Stock Holding History

Candriam SCA’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1M Sell
208,054
-106,968
-34% -$5.81M 0.05% 261
2026
Q1 		$18.3M Buy
+315,022
New +$17.1M 0.1% 206
2025
Q3 		– Sell
-74,717
Closed -$2.43M – 693
2025
Q2 		$2.43M Sell
74,717
-38,673
-34% -$1.27M 0.01% 472
2025
Q1 		$4.28M Sell
113,390
-720
-0.6% -$57.6K 0.03% 363
2024
Q4 		$9.34M Buy
+114,110
New +$11.3M 0.05% 269
2023
Q2 		– Sell
-12,070
Closed -$416K – 835
2023
Q1 		$416K Buy
+12,070
New +$512K ﹤0.01% 814

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Candriam SCA's PCVX Position: Q2 2026 in Review

Candriam SCA reduced its Vaxcyte (PCVX) stake by 34% in Q2 2026, selling an estimated $5.81M and leaving 208,054 shares worth $12.1M. The position accounts for 0.05% of the portfolio, ranked #261.

Candriam SCA first reported a position in PCVX in Q1 2023 and has held it in 6 quarters since. The position peaked at $18.3M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Candriam SCA held 208,054 shares of Vaxcyte worth $12.1M as of Q2 2026.
  • Candriam SCA sold 106,968 Vaxcyte shares in Q2 2026, an estimated $5.81M.
  • Vaxcyte made up 0.05% of Candriam SCA's portfolio in Q2 2026, its #261 holding.
  • Candriam SCA first reported a position in Vaxcyte in Q1 2023 and has held it in 6 quarters since.
  • Candriam SCA's Vaxcyte position peaked at $18.3M in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.